Peer-reviewed veterinary case report
Pan-ERBB inhibitors as treatment for canine brain tumors
By Noguchi, Shunsuke & Yasumura, Moeka·Published in Veterinary research communications·2023·Graduate School of Veterinary Science, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Potential therapeutic efficiency of pan-ERBB inhibitors for canine glioma.
- Species:
- dog
Plain-English summary
A study looked at a type of brain tumor called glioma in dogs, which is known for having a poor prognosis. Researchers tested two drugs, afatinib and dacomitinib, that target a specific protein involved in tumor growth. These drugs were found to effectively reduce tumor cell survival and potentially extend the life of dogs with this condition. While this research is still in the early stages, it suggests that targeting the ERBB4 protein could be a promising approach for treating canine gliomas.
People also search for: dog brain tumor treatment · canine glioma prognosis · afatinib for dogs with cancer
Abstract
Canine glioma is one of the most common brain tumors with poor prognosis, making effective chemotherapy highly desirable. Previous studies have suggested that ERBB4, a signaling molecule involving one of the epidermal growth factor receptors (EGFR), may be a promising therapeutic target. In this study, the anti-tumor effects of pan-ERBB inhibitors, which can inhibit the phosphorylation of ERBB4, were evaluated both in vitro and in vivo using a canine glioblastoma cell line. The results demonstrated that both afatinib and dacomitinib effectively reduced the expression of phosphorylated ERBB4, and significantly decreased the number of viable cells, ultimately prolonging the survival time of orthotopically xenografted mice. Further downstream of ERBB4, afatinib was found to suppress the expression of phosphorylated Akt and phosphorylated Extracellular signal-related kinases1 and 2 (ERK1/2) and induced apoptotic cell death. Thus, pan-ERBB inhibition is a promising therapeutic strategy for the treatment of canine gliomas.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36991174/